A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0375521 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0631 (Electronic) Linking ISSN: 00243205 NLM ISO Abbreviation: Life Sci Subsets: MEDLINE
    • Publication Information:
      Publication: <2008->: Amsterdam : Elsevier
      Original Publication: Oxford; Elmsford, N. Y. [etc.] Pergamon Press.
    • Subject Terms:
      Acarbose/*therapeutic use ; Adamantane/*analogs & derivatives ; Biomarkers/*analysis ; Diabetes Mellitus, Type 2/*drug therapy ; Dipeptides/*therapeutic use ; Hypoglycemic Agents/*therapeutic use ; Vildagliptin/*therapeutic use; Adamantane/therapeutic use ; Blood Glucose/analysis ; Dipeptidyl-Peptidase IV Inhibitors/therapeutic use ; Female ; Follow-Up Studies ; Glycated Hemoglobin/analysis ; Glycoside Hydrolase Inhibitors/therapeutic use ; Humans ; Male ; Middle Aged ; Prognosis
    • Abstract:
      As a complicated metabolic disorder, type 2 diabetes mellitus (T2DM) is becoming a major health concern worldwide. Drugs including acarbose, saxagliptin and vildagliptin are applied, but their efficacy is still required to be compared. Therefore, the study aimed to evaluate the efficacy and safety of acarbose, saxagliptin and vildagliptin in the treatment of T2DM. Ninety patients diagnosed with T2DM were treated with acarbose, saxagliptin and vildagliptin, respectively (30 patients for each drug). All patients were examined at 0, 4 and 12 weeks after treatment with vital signs recorded. Fasting blood glucose and blood biochemical indices were analyzed. In addition, fecal samples were taken for microbial macrogenome sequencing and safety evaluation within 12 weeks after treatment. Blood glucose level decreased at 4 and 12 weeks after treatment, and the total cholesterol (TC) and high-density lipoprotein (HDL) levels at 12 weeks were different. Genus abundance of intestinal flora was altered at different time points. Acarbose increased Butyricimonas level first and then decreased it during drug treatment. Saxagliptin increased Megamonas and decreased Turicibacter genus level gradually. Pseudomonas, Klebsiella, Blautia, Faecalibacterium and Roseburia levels fluctuated after Vildagliptin treatment, which increased fasting C-peptide level greater than the other two drugs. Saxagliptin showed higher adverse reactions than acarbose and vildagliptin. Collectively, acarbose, vildagliptin, and saxagliptin can effectively reduce the HbA1c level and affect the intestinal flora distribution in T2DM patients, and the adverse reactions of acarbose and vildagliptin are less than saxagliptin, providing alternative strategies for the treatment of T2DM.
      (Copyright © 2021 Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Acarbose; Efficacy; Intestinal flora; Saxagliptin; Type 2 diabetes mellitus; Vildagliptin
    • Accession Number:
      0 (Biomarkers)
      0 (Blood Glucose)
      0 (Dipeptides)
      0 (Dipeptidyl-Peptidase IV Inhibitors)
      0 (Glycated Hemoglobin A)
      0 (Glycoside Hydrolase Inhibitors)
      0 (Hypoglycemic Agents)
      0 (hemoglobin A1c protein, human)
      9GB927LAJW (saxagliptin)
      I6B4B2U96P (Vildagliptin)
      PJY633525U (Adamantane)
      T58MSI464G (Acarbose)
    • Publication Date:
      Date Created: 20210118 Date Completed: 20210412 Latest Revision: 20221207
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/j.lfs.2021.119069
    • Accession Number:
      33460667